FDA provides a complete response letter for Digestive Care's PANCRECARB

Editorial Checklist Reviewed
Sep 15 2009NewsGuard 100/100 Score

Digestive Care, Inc. (DCI) announced today that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) and has moved closer to obtaining approval of its New Drug Application (NDA) for PANCRECARB((R) )(pancrelipase) used for the treatment of Exocrine Pancreatic Insufficiency.

DCI has been working closely with the FDA throughout the NDA process and will submit a complete and timely response to the Agency's requests. DCI is not required to conduct additional clinical trials on PANCRECARB((R) )prior to NDA approval. "We are pleased to have reached this important milestone and are committed to satisfying the Agency's remaining requests," said Dr. Tibor Sipos, President and Chief Scientific Officer.

Source:

http://www.digestivecare.com

Posted in: Drug Trial News | Medical Condition News

Tags: , ,

Comments (0)

Suggested Reading

Frequent ultra-processed food consumption raises mortality risks, especially in women
High levels of microplastics found in prostate tumors, possibly linked to take-out food
Limiting fast-food outlets can reduce childhood overweight and obesity
Not all ultra-processed foods are made alike: Researchers warn against villainizing entire food group
Online food shopping: Are you getting the information you need?
Ultra-processed food linked to weight gain and lower well-being in adolescents
Social media normalizes unhealthy food choices, shaping youth habits and brand loyalty
Ultra-processed foods dominate children's diets from toddlerhood to middle childhood

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Six common flying with food allergies myths